Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 98.25% is in line with its 5-year average of 91.92%, near the high end of its 5-year range (-223.01%–100.00%).
172.38% above its 12-month average of 36.07%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
98.25%
GROSS MARGIN AVG TTM
36.07%
GROSS MARGIN AVG 3Y
96.43%
GROSS MARGIN AVG 5Y
91.92%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+172.38%
CURRENT VS 3Y AVG
+1.89%
CURRENT VS 5Y AVG
+6.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+138.44%
vs the sector median at left
Tango Therapeutics, Inc.
Market Cap
$3.57B
Gross Margin
98.25%
TTM Avg
36.07%
3Y Avg
96.43%
5Y Avg
91.92%
Market Cap
$3.54B
Gross Margin
66.09%
TTM Avg
33.05%
3Y Avg
41.52%
5Y Avg
61.02%
Market Cap
$3.52B
Gross Margin
71.45%
TTM Avg
69.72%
3Y Avg
68.83%
5Y Avg
69.16%
Market Cap
$3.64B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.48B
Gross Margin
-43.89%
TTM Avg
0.67%
3Y Avg
45.02%
5Y Avg
61.14%
Market Cap
$3.44B
Gross Margin
-360.00%
TTM Avg
-180.00%
3Y Avg
-491.57%
5Y Avg
-334.18%
Market Cap
$3.38B
Gross Margin
91.13%
TTM Avg
91.57%
3Y Avg
93.72%
5Y Avg
94.38%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | $3.57B | 98.25% | 36.07% | 96.43% | 91.92% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 72.09% | 68.25% | 67.74% | 66.97% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 66.09% | 33.05% | 41.52% | 61.02% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 71.45% | 69.72% | 68.83% | 69.16% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | 0.00% | 0.00% | 0.00% | 0.00% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -43.89% | 0.67% | 45.02% | 61.14% |
| Celcuity Inc. (CELC)vs › | $3.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -360.00% | -180.00% | -491.57% | -334.18% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 91.13% | 91.57% | 93.72% | 94.38% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
98.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 80.35% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 94.29% |
| 2023-06-30 | 89.67% |
| 2023-03-31 | 74.71% |
| 2022-12-31 | 77.35% |
| 2022-09-30 | 82.37% |
| 2022-06-30 | 88.11% |
| 2022-03-31 | 88.36% |
| 2021-12-31 | 89.91% |
| 2021-09-30 | -223.01% |
| 2021-06-30 | 97.45% |
| 2021-03-31 | 93.02% |
| 2020-12-31 | 95.33% |
| 2020-09-30 | 215.24% |
| 2020-06-30 | -119.77% |
| 2020-03-31 | -129.72% |
